ScandiDos ABOSTO:SDOS 47 3-Year RORE % is -74.29 as of Apr. 2026. GuruFocus rates OSTO:SDOS with a GF Score™ of 47/100 and a GF Value™ of kr1.15 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 782 Medical Devices & Instruments companies, ScandiDos AB ranks worse than 88.49% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
ScandiDos AB's 3-Year RORE % for the quarter that ended in Apr. 2026 was -74.29%.
The industry rank for ScandiDos AB's 3-Year RORE % or its related term are showing as below:
OSTO:SDOS's 3-Year RORE % is ranked worse than 88.49% of 782
companies
in the Medical Devices & Instruments industry
Industry Median: -4.23
vs OSTO:SDOS: -74.29
ScandiDos AB (OSTO:SDOS) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
ScandiDos AB 3-Year RORE % Related Terms
ScandiDos AB 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for ScandiDos AB's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:SDOS vs ABT, SYK, MDT: 3-Year RORE % Comparison
For the Medical Devices subindustry, ScandiDos AB's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ScandiDos AB 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ScandiDos AB's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where ScandiDos AB's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Apr. 2026 and 3-year before.
ScandiDos AB (OSTO:SDOS) has a 3-Year RORE % of -74.29 as of Apr. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on ScandiDos AB and its competitors. According to the industry distribution chart, ScandiDos AB ranks #692 out of 782 companies in the Medical Devices & Instruments industry, placing it in the top 88.5%.
Is ScandiDos AB's 3-Year RORE % too high?
ScandiDos AB's current 3-Year RORE % is -74.29. Based on the distribution chart, ScandiDos AB ranks #692 out of 782 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, ScandiDos AB has a GF Score™ of 47/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ScandiDos AB's 3-Year RORE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ScandiDos AB ranks #692 out of 782 companies for 3-Year RORE %. This places ScandiDos AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on ScandiDos AB and its competitors. ScandiDos AB's current 3-Year RORE % is -74.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ScandiDos AB stock overvalued right now?
Based on GuruFocus' analysis, ScandiDos AB (OSTO:SDOS) is currently considered Modestly Undervalued. The stock's GF Value™ is kr1.15, compared to a current price of kr0.83 — trading 27.8% below its estimated fair value. The current 3-Year RORE % is -74.29. ScandiDos AB's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For ScandiDos AB (OSTO:SDOS), the current 3-Year RORE % is -74.29 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ScandiDos AB (OSTO:SDOS) Overvalued in 2026?
Based on GuruFocus' analysis, ScandiDos AB stock appears to be undervalued.
The current stock price of kr0.83 is trading 27.8% below its estimated GF Value™ of kr1.15.
GuruFocus considers ScandiDos AB to be Modestly Undervalued.
Key valuation signals for OSTO:SDOS:
3-Year RORE %: -74.29
GF Value™: kr1.15 vs. price of kr0.83 (27.8% below fair value)
No single metric tells the full story. See the OSTO:SDOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ScandiDos AB is engaged in providing radiation therapy for cancer. Its product, Delta4 Phantom+, and its various hardware and software options are at the heart of everything ScandiDos does, from product development and production to marketing, sales, and customer support. With Delta4 HexaMotion ScandiDos has successfully developed a motion platform that recreates the movement of the tumor in six dimensions and independently simulates the patient's breathing movement.
47GF Score
Get the complete analysis for OSTO:SDOS
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SDOS has been successfully added to your 
